Testing the NMDA, Long-Term Potentiation, and Cholinergic Hypotheses of Spatial Learning

Total Page:16

File Type:pdf, Size:1020Kb

Testing the NMDA, Long-Term Potentiation, and Cholinergic Hypotheses of Spatial Learning Neuroscience & Biobehavioral Reviews, Vol. 22, No. 2, pp. 181–193, 1998 ᭧ 1998 Elsevier Science Ltd. All rights reserved Pergamon Printed in Great Britain 0149-7634/98 $32.00 + .00 PII: S0149-7634(97)00005-5 Testing the NMDA, Long-term Potentiation, and Cholinergic Hypotheses of Spatial Learning DONALD PETER CAIN* Department of Psychology and Graduate Program in Neuroscience, University of Western Ontario, London, Ontario N6A 5C2, Canada CAIN, D. P. Testing the NMDA, long-term potentiation, and cholinergic hypotheses of spatial learning. NEUROSCI BIOBEHAV REV 22(2), 181–193, 1998.—The problems and issues associated with the use of pharmacological antagonists in studies on learning and memory are considered in a review of the role of N-methyl-d-aspartate (NMDA) receptors, NMDA receptor-mediated long-term potentiation (LTP), and muscarinic receptors in spatial learning in the water maze. The evidence indicates that neither NMDA nor muscarinic receptors, nor NMDA receptor-mediated LTP, are required for spatial learning, although they might normally contribute to it. Detailed behavioral analyses have indicated that the water maze task is more complex than generally has been appreciated, and has a number of dissociable components. Naive rats trained under NMDA or muscarinic antagonism display sensorimotor disturbances that interfere with their ability to acquire the task. Rats made familiar with the general requirements of the task can learn the location of a hidden platform readily under NMDA or muscarinic antagonism. The ability of a rat to acquire the water maze task depends on its ability to apply instinctive behaviors to performance of the task in an adaptive manner. The instinctive behaviors undergo modification as the rat learns the general strategies required in the task. The evidence suggests that at least some of the plastic changes involved in acquiring the task occur in existing neural circuits situated in widespread areas of the brain, including sensory and motor structures in the cortex and elsewhere, and are therefore difficult to distinguish from existing sensorimotor mechanisms. More generally, the findings indicate the difficulty of inferring the occurrence or nonoccurrence of learning from behavior, and the difficulty of causally linking the action of particular receptor populations with the formation of specific memories. ᭧ 1998 Elsevier Science Ltd. All rights reserved. N-Methyl-d-aspartate NMDA Scopolamine Muscarinic receptor Spatial learning Water maze Sensorimotor disturbances Behavior CERTAIN PERIODS in the history of brain research have More recently, behavioral neuroscience has experienced been dominated by a search for the mechanisms of learning a strong resurgence of interest in the engram. Two develop- and memory. Karl Lashley, the father of modern behavioral ments during the 1970s were probably important in this neuroscience, spent much of the period from 1920 to 1950 resurgence. First, Eric Kandel and his colleagues set out searching for the engram in a long series of learning experi- to map the nervous system of Aplysia, a simple invertebrate, ments involving rats and monkeys with brain lesions. For and to identify the neurons and events required for simple Lashley the engram represented the sites of lasting change in forms of behavioral learning (14). Second, Bliss and Lomo the nervous system—presumably specific synapses—that (10) discovered long-term potentiation (LTP), a relatively were associated with particular instances of behavioral learn- long-lasting form of neural plasticity that could be artificially ing, and were necessary for it to occur. His approach of beha- induced in the brain of mammals by electrical stimulation. viorally training rats to discriminate visual stimuli or negotiate The first development showed that detailed knowledge of mazes set the tone of such research for years. Lashley’s con- relevant neural circuitry was beneficial and perhaps even tributions are usually, but incompletely, summed up by the necessary, and that this knowledge, together with electro- ‘‘principle of mass action’’, the conclusion that for complex physiological analysis, could identify the nature and location tasks such as learning to traverse a maze, the amount learned of the engram in a simple animal. The second development and remembered was proportional to the amount of remaining provided a laboratory model of the kind of synaptic plasticity neocortex; the location ofthe damage mattered little. Although that could underlie complex forms of learning in mammals the common view that Lashley failed in his attempts to locate (9). LTP appeared to embody the activity of the ‘‘Hebb the engram for some forms of learning is mistaken (104), the synapse’’, a modifiable synapse that Donald Hebb, Lashley’s perceived negativity of his findings, and the accumulating student, proposed in 1949 as a learning mechanism. evidence for the localization of function in the neocortex, led The idea that the hippocampus was uniquely important many researchers to discredit his conclusions. for engram formation stemmed from the discovery in the * Tel.: +1 519 6792111, ext. 4628; Fax: +1 519 6613961; E-mail: [email protected] 181 182 CAIN 1950s that human patients with hippocampal removals movement by visual and other sensory input, climbing experienced severe disturbances in learning and memory onto and standing on the platform), there must be pre- (87). Later, based on animal research, O’Keefe and Nadel existing neural circuits that the rat brings to the water maze (71) proposed that the hippocampus served as a spatial map. task for its successful acquisition (51,100,102,104,117), in Their hypothesis was supported by the finding that indivi- addition to engrams that might be formed by neuroplastic dual complex spike cells in the hippocampus, called place processes during training. cells, fired when an animal was in a specific location within Successful acquisition of the water maze task requires an an environment (70). This suggested that place cells coded animal to navigate efficiently from any starting point in the spatial locations in the environment, giving anatomical and pool to a specific location containing the hidden platform. functional support to the hypothesis that the hippocampus Whishaw and Mittleman (115) showed that normal rats served as a spatial map that was crucial for spatial learn- made use of a number of different spatial navigation ing—the learning of a location in the environment in strategies in acquiring the water maze task, and that these relation to cues in that environment. The fact that damage strategies were considerably more complex than had been to the hippocampus or related structures severely disrupted thought. They suggested that ‘‘some deficits in spatial acquisition of tasks that required spatial information was navigation that follow brain damage may be as easily consistent with their hypothesis (65,69). attributed to the loss of search strategies as to the loss of a Further impetus for the idea that the hippocampus might hypothetical subsystem of memory’’ (p. 428). This general be important for engram formation came from research approach led to an extensive series of experiments, the showing that LTP occurred most readily in the hippo- conclusion of which was that muscarinic antagonists disrupt campus. Although hippocampal LTP has been theoretically a sensorimotor subsystem important for the selection of linked to various kinds of learning, it has been most closely behavioral strategies required to solve the water maze linked to spatial learning (15,63,64). LTP at most hippo- task, and do not prevent spatial learning per se campal synapses was found to be dependent on activity at N- (109,110,117,118). The question whether experimental methyl-d-aspartate (NMDA) receptors (17,34,64), and treatments affect the selection of behavioral strategies for NMDA receptor antagonists were found to severely disrupt acquiring the water maze task, or even basic sensory acquisition of spatial learning tasks (63,64). This suggested processing or motor control mechanisms, is important for that NMDA receptor-mediated LTP in the hippocampus understanding drug and lesion effects. established the engram for spatial learning. The relevance of this question is that all conclusions This review will evaluate the hypothesis that NMDA about the neural mechanisms of learning, conceived of as receptor-mediated LTP in the hippocampus is necessary changes in conduction through specific neural circuits, are for establishing the engram for spatial learning. The number inferences from observable behavior. For inferences about of laboratory tasks that could potentially involve aspects of spatial learning to be valid, the behavioral changes cannot spatial learning for their acquisition is large, so the discus- have resulted from the disruptive effects of an experimental sion will focus on selected studies involving the water maze. treatment on the mechanisms involved in producing the This task requires a rat or mouse to swim in a circular pool instinctive behaviors required to perform the task. Under- of water 1–2 m in diameter until it finds and climbs onto a standing the effects of treatments on instinctive behaviors, small platform hidden just beneath the surface, which as well as on the engram, is vital for arriving at a useful and provides the only refuge. This task is well suited for the complete understanding of learning and memory (102,104). study of spatial learning because it requires the animal to The difficulty of knowing whether experimental treat- learn to swim to a specific location using visual cues in the ments have affected pre-existing neural circuits that produce room (61,71,96). Normal rats learn to do this quickly, but instinctive behavior, or the engram, or both, is a very diffi- rats given NMDA antagonists or hippocampal lesions do cult problem for even the simplest forms of learning. A poorly on this task (63–65). further complication is the fact that instinctive behaviors In addition to a hypothesized role for NMDA receptor- themselves can be modified by experience. There are mediated hippocampal LTP in spatial learning, there is evi- many examples of this from a large variety of species.
Recommended publications
  • Dextromethorphan Attenuates Sensorineural Hearing Loss in an Animal Model and Population-Based Cohort Study
    International Journal of Environmental Research and Public Health Article Dextromethorphan Attenuates Sensorineural Hearing Loss in an Animal Model and Population-Based Cohort Study Hsin-Chien Chen 1,* , Chih-Hung Wang 1,2 , Wu-Chien Chien 3,4 , Chi-Hsiang Chung 3,4, Cheng-Ping Shih 1, Yi-Chun Lin 1,2, I-Hsun Li 5,6, Yuan-Yung Lin 1,2 and Chao-Yin Kuo 1 1 Department of Otolaryngology-Head and Neck Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan; [email protected] (C.-H.W.); [email protected] (C.-P.S.); [email protected] (Y.-C.L.); [email protected] (Y.-Y.L.); [email protected] (C.-Y.K.) 2 Graduate Institute of Medical Sciences, National Defense Medical Center, Taipei 114, Taiwan 3 School of Public Health, National Defense Medical Center, Taipei 114, Taiwan; [email protected] (W.-C.C.); [email protected] (C.-H.C.) 4 Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan 5 Department of Pharmacy Practice, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan; [email protected] 6 School of Pharmacy, National Defense Medical Center, Taipei 114, Taiwan * Correspondence: [email protected]; Tel.: +886-2-8792-7192; Fax: +886-2-8792-7193 Received: 31 July 2020; Accepted: 28 August 2020; Published: 31 August 2020 Abstract: The effect of dextromethorphan (DXM) use in sensorineural hearing loss (SNHL) has not been fully examined. We conducted an animal model and nationwide retrospective matched-cohort study to explore the association between DXM use and SNHL.
    [Show full text]
  • A Case Study on Addressing Abuse of a Safe and Effective Drug David C
    Spangler et al. Substance Abuse Treatment, Prevention, and Policy (2016) 11:22 DOI 10.1186/s13011-016-0067-0 DEBATE Open Access Dextromethorphan: a case study on addressing abuse of a safe and effective drug David C. Spangler1, Catherine M. Loyd1* and Emily E. Skor1,2 Abstract Background: Dextromethorphan is a safe, effective cough suppressant, available without a prescription in the United States since 1958. Due to a perceived prevalence of abuse of dextromethorphan by teens, in 2007 the Drug Enforcement Administration requested the Food and Drug Administration evaluate whether dextromethorphan should be recommended for scheduling under the Controlled Substances Act. The Food and Drug Administration held an Advisory Committee meeting in 2010 to provide a scientific and medical evaluation of dextromethorphan and its abuse potential. Discussion: To address reports of abuse, particularly by teens in the United States, the Consumer Healthcare Products Association initiated an abuse mitigation plan in 2010 with specific goals related to awareness of the behavior, perception of risk, social disapproval, and access to the products. In identifying abuse interventions, experts acknowledge that substance abuse among teens is a highly complex behavior and indicate that the best course of action is to address prevention by focusing on the factors that impact teen behavior. Conclusion: It is noteworthy that the annual prevalence of over-the-counter cough medicine abuse has sharply decreased since 2010. While a true cause-and-effect relationship cannot be assured, the Consumer Healthcare Products Association and its member companies believe that the increased awareness of the issue since the 2010 Food and Drug Administration Advisory Committee meeting, and the subsequent implementation of a well-delivered and targeted abuse mitigation plan that addressed the levers influencing teen decisions is contributing to the observed reduction in abuse.
    [Show full text]
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • Interplay Between Gating and Block of Ligand-Gated Ion Channels
    brain sciences Review Interplay between Gating and Block of Ligand-Gated Ion Channels Matthew B. Phillips 1,2, Aparna Nigam 1 and Jon W. Johnson 1,2,* 1 Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA; [email protected] (M.B.P.); [email protected] (A.N.) 2 Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260, USA * Correspondence: [email protected]; Tel.: +1-(412)-624-4295 Received: 27 October 2020; Accepted: 26 November 2020; Published: 1 December 2020 Abstract: Drugs that inhibit ion channel function by binding in the channel and preventing current flow, known as channel blockers, can be used as powerful tools for analysis of channel properties. Channel blockers are used to probe both the sophisticated structure and basic biophysical properties of ion channels. Gating, the mechanism that controls the opening and closing of ion channels, can be profoundly influenced by channel blocking drugs. Channel block and gating are reciprocally connected; gating controls access of channel blockers to their binding sites, and channel-blocking drugs can have profound and diverse effects on the rates of gating transitions and on the stability of channel open and closed states. This review synthesizes knowledge of the inherent intertwining of block and gating of excitatory ligand-gated ion channels, with a focus on the utility of channel blockers as analytic probes of ionotropic glutamate receptor channel function. Keywords: ligand-gated ion channel; channel block; channel gating; nicotinic acetylcholine receptor; ionotropic glutamate receptor; AMPA receptor; kainate receptor; NMDA receptor 1. Introduction Neuronal information processing depends on the distribution and properties of the ion channels found in neuronal membranes.
    [Show full text]
  • Viewed the Existence of Multiple Muscarinic CNS Penetration May Occur When the Blood-Brain Barrier Receptors in the Mammalian Myocardium and Have Is Compromised
    BMC Pharmacology BioMed Central Research article Open Access In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine G Howell III†1, L West†1, C Jenkins2, B Lineberry1, D Yokum1 and R Rockhold*1 Address: 1Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson, MS 39216, USA and 2Tougaloo College, Tougaloo, MS, USA Email: G Howell - [email protected]; L West - [email protected]; C Jenkins - [email protected]; B Lineberry - [email protected]; D Yokum - [email protected]; R Rockhold* - [email protected] * Corresponding author †Equal contributors Published: 18 August 2005 Received: 06 October 2004 Accepted: 18 August 2005 BMC Pharmacology 2005, 5:13 doi:10.1186/1471-2210-5-13 This article is available from: http://www.biomedcentral.com/1471-2210/5/13 © 2005 Howell et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: Muscarinic receptor mediated adverse effects, such as sedation and xerostomia, significantly hinder the therapeutic usefulness of first generation antihistamines. Therefore, second and third generation antihistamines which effectively antagonize the H1 receptor without significant affinity for muscarinic receptors have been developed. However, both in vitro and in vivo experimentation indicates that the third generation antihistamine, desloratadine, antagonizes muscarinic receptors. To fully examine the in vivo antimuscarinic efficacy of desloratadine, two murine and two rat models were utilized. The murine models sought to determine the efficacy of desloratadine to antagonize muscarinic agonist induced salivation, lacrimation, and tremor.
    [Show full text]
  • From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia J
    REVIEW The Neuropsychopharmacology of Phencyclidine: From NMDA Receptor Hypofunction to the Dopamine Hypothesis of Schizophrenia J. David Jentsch, Ph.D., and Robert H. Roth, Ph.D. Administration of noncompetitive NMDA/glutamate effects of these drugs are discussed, especially with regard to receptor antagonists, such as phencyclidine (PCP) and differing profiles following single-dose and long-term ketamine, to humans induces a broad range of exposure. The neurochemical effects of NMDA receptor schizophrenic-like symptomatology, findings that have antagonist administration are argued to support a contributed to a hypoglutamatergic hypothesis of neurobiological hypothesis of schizophrenia, which includes schizophrenia. Moreover, a history of experimental pathophysiology within several neurotransmitter systems, investigations of the effects of these drugs in animals manifested in behavioral pathology. Future directions for suggests that NMDA receptor antagonists may model some the application of NMDA receptor antagonist models of behavioral symptoms of schizophrenia in nonhuman schizophrenia to preclinical and pathophysiological research subjects. In this review, the usefulness of PCP are offered. [Neuropsychopharmacology 20:201–225, administration as a potential animal model of schizophrenia 1999] © 1999 American College of is considered. To support the contention that NMDA Neuropsychopharmacology. Published by Elsevier receptor antagonist administration represents a viable Science Inc. model of schizophrenia, the behavioral and neurobiological KEY WORDS: Ketamine; Phencyclidine; Psychotomimetic; widely from the administration of purportedly psychot- Memory; Catecholamine; Schizophrenia; Prefrontal cortex; omimetic drugs (Snyder 1988; Javitt and Zukin 1991; Cognition; Dopamine; Glutamate Jentsch et al. 1998a), to perinatal insults (Lipska et al. Biological psychiatric research has seen the develop- 1993; El-Khodor and Boksa 1997; Moore and Grace ment of many putative animal models of schizophrenia.
    [Show full text]
  • Presence of Methoxetamine in Drug Samples Delivered As Ketamine for Substance Analysis
    Is this really ketamine? Presence of methoxetamine in drug samples delivered as ketamine for substance analysis P. Quintana2, Á. Palma1,5, M. Grifell1,2, J. Tirado3,5, C. Gil2, M. Ventura2, I. Fornís3, S. López2, V. Perez1,5, M. Torrens1,3,5, M. Farré3,4,5, L. Galindo1,3,5 1Institut de Neuropsiquiatria i Addiccions, Parc de Salut Mar, Barcelona, Spain 2Asocicación Bienestar y Desarrollo, Energy Control, Barcelona, Spain 3IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain 4Hospital Germans Trías i Pujol, Servei de Farmacología Clínica, Barcelona, Spain 5Departament de Psiquiatria, Universitat Autònoma de Barcelona, Barcelona, Spain Introduction New psychoactive substances (NPS) are drugs that have recently become available, and are not world-wide regulated. They often intend to mimic the effect of controlled drugs (1), becoming a public health concern. In 2014, 101 new substances were reported for the first time in the EU (2). Methoxetamine, an NPS, is a dissociative hallucinogenic acting as a NMDA receptor antagonist, clinically and pharmacologically similar to Ketamine (3). It differs from ketamine on its higher potency and duration as well as on its possible serotonergic activity, probably leading to more severe side effects. It has been one of the 6 substances requiring risk assessment by EMCDDA during 2014(3), and several case reports have described fatal outcomes related with its use(4). Objective Material and methods The aim of this study was 1) to explore the presence of methoxetamine from the All samples analyzed from January 2010 to March 2015 in which methoxetamine was samples handled to, and analyzed by Energy Control and 2) to determine whether found were studied.
    [Show full text]
  • Lithium Stimulates Glutamate "Release" and Inositol 1,4,5
    Proc. Nat!. Acad. Sci. USA Vol. 91, pp. 8358-8362, August 1994 Neurobiology Lithium stimulates glutamate "release" and inositol 1,4,5-trisphosphate accumulation via activation of the N-methyl-D-aspartate receptor in monkey and mouse cerebral cortex slices (manic depression/bipolar disorder/primates) JOHN F. DIXON, GEORGYI V. Los, AND LOWELL E. HOKIN* Department of Pharmacology, University of Wisconsin Medical School, 1300 University Avenue, Madison, WI 53706 Communicated by Henry Lardy, May 9, 1994 (received for review February 18, 1994) ABSTRACT Beginning at therapeutic concentrations (1- showed lithium-stimulated increases in Ins(1,4,5)P3 and 1.5 mM), the anti-manic-depressive drug lithium stimulated inositol 1,3,4,5-tetrakisphosphate (2). the release of glutamate, a major excitatory neurotransmitter In the case of rhesus monkey, neither inositol nor an in the brain, in monkey cerebral cortex slices in a time- and agonist was required to demonstrate lithium-stimulated ac- concentration-dependent manner, and this was associated with cumulation of Ins(1,4,5)P3 (3). This suggested that an endog- increased inositol 1,4,5-trisphosphate [Ins(1,4,5)P3] accumu- enous neurotransmitter was involved in the lithium effect. lation. (±)-3-(2-Carboxypiperazin-4-yl)propyl-1-phosphoric We show here that, beginning at therapeutic concentrations, acid (CPP), dizocilpine (MK-801), ketamine, and Mg2+- lithium stimulated the release ofglutamate in rhesus monkey antagonists to the N-methyl-D-aspartate (NMDA) recep- and mouse cerebral cortex slices, and this in turn increased tor/channel complex selectively inhibited lithium-stimulated accumulation of Ins(1,4,5)P3 via activation of the N-methyl- Ins(t,4,5)P3 accumulation.
    [Show full text]
  • Muscarinic Cholinergic Receptors in Developing Rat Lung
    1136 WHITSETT AND HOLLINGER Am J Obstet Gynecol 126:956 Michaelis LL 1978 The effects of arterial COztension on regional myocardial 2. Belik J, Wagerle LC, Tzimas M, Egler JM, Delivoria-Papadopoulos M 1983 and renal blood flow: an experimental study. J Surg Res 25:312 Cerebral blood flow and metabolism following pancuronium paralysis in 18. Leahy FAN. Cates D. MacCallum M. Rigatto H 1980 Effect of COz and 100% newborn lambs. Pediatr Res 17: 146A (abstr) O2 on cerebral blood flow in preterm infants. J Appl Physiol48:468 3. Berne RM, Winn HR, Rubio R 1981 The local regulation of cerebral blood 19. Norman J, MacIntyre J, Shearer JR, Craigen IM, Smith G 1970 Effect of flow. Prog Cardiovasc Dis 24:243 carbon dioxide on renal blood flow. Am J Physiol 219:672 4. Brann AW Jr, Meyers RE 1975 Central nervous system findings in the newborn 20. Nowicki PT, Stonestreet BS, Hansen NB, Yao AC, Oh W 1983 Gastrointestinal monkey following severe in utero partial asphyxia. Neurology 25327 blood flow and oxygen in awake newborn piglets: the effect of feeding. Am 5. Bucciarelli RL, Eitzman DV 1979 Cerebral blood flow during acute acidosis J Physiol245:G697 in perinatal goats. Pediatr Res 13: 178 21. Paulson OB, Olesen J, Christensen MS 1972 Restoration of auto-regulation of 6. Dobbing J, Sands J 1979 Comparative aspects of the brain growth spurt. Early cerebral blood flow by hypocapnia. Neurology 22:286 Hum Dev 3:79 22. Peckham GJ. Fox WW 1978 Physiological factors affecting pulmonary artery 7. Fox WW 1982 Arterial blood gas evaluation and mechanical ventilation in the pressure in infants with persistent pulmonary hypertension.J Pediatr 93: 1005 management of persistent pulmonary hypertension of the neonate.
    [Show full text]
  • Palliative Care
    World Health Organisation Essential Medicines List for Children (EMLc); Palliative Care CONSULTATION DOCUMENT Prepared by Anita Aindow Medicines Information Pharmacist Alder Hey Children’s Hospital, Liverpool, UK Dr Lynda Brook Macmillan Consultant in Paediatric Palliative Care Alder Hey Children’s Hospital, Liverpool, UK Acknowledgements Professor Tim Eden Professor of Paediatric Oncology, Royal Manchester Children’s Hospital, Manchester, UK Mr Anthony Nunn, Clinical Director of Pharmacy, Alder Hey Children’s Hospital, Liverpool, UK Dr Suzanne Hill Scientist, Policy, Access and Rational Use: Medicines Policy and Standards World health Authority, Geneva For their help and guidance in the preparation of this document Correspondence to Dr Lynda Brook, Macmillan Consultant in Paediatric Palliative Care Department of Paediatric Oncology, Royal Liverpool Children’s Hospital, Eaton Road, Liverpool, L12 2AP Tel: 0151 252 5187 Fax: 0151 252 5676 E-mail: [email protected] DECLARATION OF CONFLICT OF INTERESTS : None June 2008 WHO EMLc: Palliative Care – June 2008 CONTENTS Abstract 3 Summary of recommendations 5 Background 15 Methods 17 Identification of priorities for pharmacological management in palliative 17 care for children Pharmacological management of identified symptoms 17 Results 19 PRIORITIES FOR PHARMACOLOGICAL MANAGEMENT IN PALLIATIVE CARE FOR 19 CHILDREN ESSENTIAL MEDICINES FOR PHARMACOLOGICAL MANAGEMENT IN PALLIATIVE 23 CARE FOR CHILDREN Fatigue and weakness 24 Pain 29 Anorexia and weight loss 52 Delirium and agitation 55 Breathlessness 61 Nausea and vomiting 68 Constipation 89 Depression 95 Excess respiratory tract secretions 106 Anxiety 113 Appendix 116 2 WHO EMLc: Palliative Care – June 2008 ABSTRACT Background The World Health Organization (WHO) Essential Medicines List for Children (EMLc) aims to promote worldwide equity of access to essential medicines for children and is based on the criteria of safety, efficacy and cost effectiveness.
    [Show full text]
  • Role of Muscarinic Acetylcholine Receptors in Adult Neurogenesis and Cholinergic Seizures
    Role of Muscarinic Acetylcholine Receptors in Adult Neurogenesis and Cholinergic Seizures Rebecca L. Kow A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2014 Reding Committee: Neil Nathanson, Chair Sandra Bajjalieh Joseph Beavo Program Authorized to Offer Degree: Pharmacology ©Copyright 2014 Rebecca L. Kow University of Washington Abstract Role of Muscarinic Acetylcholine Receptors in Adult Neurogenesis and Cholinergic Seizures Rebecca L. Kow Chair of the Supervisory Committee: Professor Neil M. Nathanson Department of Pharmacology Muscarinic acetylcholine receptors (mAChRs) are G protein-coupled receptors (GPCRs) that mediate important functions in the periphery and in the central nervous systems. In the brain these receptors modulate many processes including learning, locomotion, pain, and reward behaviors. In this work we investigated the role of mAChRs in adult neurogenesis and further clarified the regulation of muscarinic agonist-induced seizures. We first investigated the role of mAChRs in adult neurogenesis in the subventricular zone (SVZ) and the subgranular zone (SGZ). We were unable to detect any modulation of adult neurogenesis by mAChRs. Administration of muscarinic agonists or antagonists did not alter proliferation or viability of adult neural progenitor cells (aNPCs) in vitro. Similarly, muscarinic agonists did not alter proliferation or survival of new adult cells in vivo. Loss of the predominant mAChR subtype in the forebrain, the M1 receptor, also caused no alterations in adult neurogenesis in vitro or in vivo, indicating that the M1 receptor does not mediate the actions of endogenous acetylcholine on adult neurogenesis. We also investigated the interaction between mAChRs and cannabinoid receptor 1 (CB1) in muscarinic agonist pilocarpine-induced seizures.
    [Show full text]
  • Janssen Research & Development, LLC Advisory Committee Briefing
    Janssen Research & Development, LLC Advisory Committee Briefing Document Esketamine Nasal Spray for Patients with Treatment-resistant Depression JNJ-54135419 (esketamine) Status: Approved Date: 16 January 2019 Prepared by: Janssen Research & Development, LLC EDMS number: EDMS-ERI-171521650, 1.0 ADVISORY COMMITTEE BRIEFING MATERIALS: AVAILABLE FOR PUBLIC RELEASE 1 Status: Approved, Date: 16 January 2019 JNJ-54135419 (esketamine) Treatment-resistant Depression Advisory Committee Briefing Document GUIDE FOR REVIEWERS This briefing document provides 3 levels of review with increasing levels of detail: The Executive Overview (Section 1, starting on page 11) provides a narrative summarizing the disease, need for novel treatments, key development program characteristics for esketamine nasal spray, study results, and conclusions. References are made to the respective supporting sections in the core document. The core document (Section 2 to Section 11, starting on page 30) includes detailed summaries and discussion in support of the Executive Overview. The appendices (starting on page 180) provide additional or more detailed information to complement brief descriptions provided in sections of the core document (e.g., demographic and baseline characteristics of the study populations, additional efficacy analyses in the Phase 3 studies, statistical methods). These appendices are referenced in the core document when relevant. This review structure allows review at varying levels of detail; however, reviewers who read at multiple levels will necessarily
    [Show full text]